Ovarian enlargement, ascites, w/ or w/o pain &/or pleural effusion, rupture of ovarian cysts w/ resultant haemoperitoneum, multiple births, arterial thromboembolism, ovarian hyperstimulation syndrome. May induce precocious puberty in patients for cryptorchidism; discontinue if signs of precocious puberty occurs. Patients w/ epilepsy, migraine, asthma, cardiac or renal disease. Perform determination of oestrogen levels & assessment of ovarian size & ultrasonography prior to treatment & at regular intervals during treatment. Female: High dosage may cause oestrogen levels to rise excessively & possibly reaching excessively high preovulatory values. Discontinue immediately if unwanted hyperstimulation occurs (ie, not as part of a treatment preparing for IVF/ET or GIFT or other assisted reproduction technique) particularly in patients w/ polycystic ovarian disease. Male: Patients w/ latent or overt cardiac failure, renal dysfunction, HTN, epilepsy or migraine or history of these conditions. Caution in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development; monitor skeletal maturation regularly.
Sign Out
